About The Study: Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery in this trial that enrolled more than 1,500 participants in the United States. A lack of treatment effect was also seen for secondary clinical outcomes including hospitalization, death, or acute care visits. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19.
Authors: Susanna Naggie, M.D., M.H.S., of the Duke University School of Medicine in Durham, North Carolina, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2022.18590)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2022.18590?guestAccessKey=57cc9ab2-90d5-4657-820e-5f19760649ba&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102122
JAMA